Pulmonx CEO Glen French retires; Steve Williamson appointed President and CEO effective March 15, 2024

Pulmonx Corp

Glen French resigns as CEO effective March 15; will serve as Senior Advisor until May 1, then remain on Board.
Steve Williamson named CEO and Board member; previously Chief Commercial Officer at Outset Medical.
Williamson receives $580k base salary, 75% target bonus, and equity grants totaling $5M (option + RSU).
Board reduces size to eight directors after Alissa Hsu Lynch declines re-election at 2024 annual meeting.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Glendon E. French

President and Chief Executive Officer

LUNG · Pulmonx Corp

Effective: 2024-03-15
Successor: Steven S. Williamson
Filed: February 21, 2024, 6:59 PM ET

On February 20, 2024, Glendon E. French resigned as President and Chief Executive Officer of Pulmonx Corporation (the “Company”), effective as of March 15, 2024

Appointed

Steven S. Williamson

President and Chief Executive Officer

LUNG · Pulmonx Corp

Effective: 2024-03-15
Filed: February 21, 2024, 6:59 PM ET

On February 19, 2024, the Company’s board of directors appointed Steven S. Williamson as the Company’s President and Chief Executive Officer and a Class II member of the board of directors, each as of the Effective Date.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Glendon E. French resigned as President and Chief Executive Officer at Pulmonx Corp.

Action: resigned
Role: President and Chief Executive Officer

Exact text from the filing

On February 20, 2024, Glendon E. French resigned as President and Chief Executive Officer of Pulmonx Corporation (the “Company”), effective as of March 15, 2024

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Steven S. Williamson was appointed as President and Chief Executive Officer at Pulmonx Corp.

Action: appointed
Role: President and Chief Executive Officer

Exact text from the filing

On February 19, 2024, the Company’s board of directors appointed Steven S. Williamson as the Company’s President and Chief Executive Officer and a Class II member of the board of directors, each as of the Effective Date.

View on SEC.gov

Pulmonx Corp filing history →

Source: SEC EDGAR

accession 0001127537-24-000012

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.